Compare ARLO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLO | RAPP |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2024 |
| Metric | ARLO | RAPP |
|---|---|---|
| Price | $13.99 | $33.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $24.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.1M | 310.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 24.34 |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | $100.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.94 | $7.73 |
| 52 Week High | $19.94 | $42.27 |
| Indicator | ARLO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 68.61 |
| Support Level | $13.15 | $25.48 |
| Resistance Level | $14.46 | $42.27 |
| Average True Range (ATR) | 0.55 | 1.83 |
| MACD | -0.09 | 0.52 |
| Stochastic Oscillator | 33.81 | 94.74 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.